Avita Medical Ltd. (AVMXY: OTCQX International) | Avita Medical Provides Update on ReCell® Success in Treating Burn Victims in Taiwan

Avita Medical Provides Update on ReCell® Success in Treating Burn Victims in Taiwan

Oct 12, 2015

OTC Disclosure News Service

Northridge, CA and Cambridge, UK

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a
regenerative medicine company specializing in the treatment of wounds and skin
defects, today announced that doctors in Taiwan have reported positive results
from using ReCell® to treat burn victims of June’s waterpark disaster, with
medics saying they have seen superior wound closure and better outcomes.

A total of 12 people have
died from burns sustained in the June 27 blast, triggered when a flammable
starch-based powder ignited during a crowded music festival at the waterpark
outside Taipei. The fire left 498 people with burn injuries, most of them
teenagers, with the average wound size covering 43% of their bodies. Officials
say 107 victims remain hospitalized, of whom 12 are still in intensive care.

Avita Medical donated 50 ReCell®
devices and sent a team to support Taiwanese medical personnel.  All of these units, and a number of purchased
devices, were distributed to 12 hospitals. To date, about 76 patients have been
treated with ReCell® and doctors contacted since the treatment began have now
reported positive outcomes in their application of Regenerative Epithelial
Suspension™ to both wounds and donor sites. Definitive conclusions
around the impact of ReCell® are difficult to draw in circumstances where
multiple treatments are being provided to meet the challenges of a mass
casualty; however, when ReCell® is part of care, it is reported that better-than-expected
outcomes are often being achieved.

“There was a great range and
variation of burn wounds, so it is heartening to hear directly from the doctors
that the regenerative healing mechanism has performed as we hoped it would,”
said Adam Kelliher, CEO of Avita Medical. “Using ReCell® was a new approach for
the surgeons, and it was being applied in extreme circumstances, so we are
pleased to be able to report benefits amongst these various anecdotal
accounts.”

One of the doctors
contacted, Dr. Yu-Ching Shih, a plastic surgeon at Taipei Veterans General
Hospital, said he had conducted four treatments with ReCell®, and reported
positive outcomes in healing and better-resulting skin quality. He observed
that the device is ‘important in accelerating healing, as we have seen that ReCell®
does help wound closure.’

Dr. Shi said in one of the
cases, donor skin shortages meant the patient could only receive ReCell® on one
thigh, while the other thigh was merely given a dressing.

“After 14 days, we could see
wound closure on the right [ReCell-treated] thigh and no progress of wound
healing on the left [untreated] thigh,” Dr. Shi said. “We will keep monitoring
results in the coming months, and it will be of particular interest to see if
ReCell® can help stop such typical scarring problems as contracture.”

Dr. Wen-Pin Kao, chief
doctor of the plastic surgery department at Changhua Christian Hospital, said
using ReCell® in conjunction with other treatments such as grafts had boosted
the survival rate of ‘skin islands’ within the wound bed by up to 90%.

“The final result is better
than we expected,” Dr Kao said. “ReCell® is showing that it can enhance the
survival rate of skin grafts. By using this, we are seeing that there is no
need for another skin graft treatment.”

 

ABOUT
RECELL®, REGENERCELL®. RENOVACELL®, AND RES™

Avita Medical’s unique proprietary technology enables a clinician to
rapidly create, at point of care in approximately 30 minutes, Regenerative
Epithelial Suspension (RES™) using a small sample of the patient’s skin. RES™
is an autologous suspension comprising the cells and wound healing factors
thought necessary to regenerate natural, healthy skin. RES™ has a broad range
of applications and can be created using specific Avita Medical devices and
applied to select treatment indications:

·        
ReCell®
for burn injuries, to repair for earlier definitive closure and superior
outcomes;

·        
ReGenerCell® for
chronic wounds, to initiate
and promote healing in unresponsive wounds;

·        
ReNovaCell®
for skin pigmentation defects, to
restore pigmentation and improve the appearance of scars and damaged skin.

 

ABOUT AVITA
MEDICAL LIMITED

Avita
Medical develops and distributes regenerative products for the treatment of a
broad range of wounds, scars and skin defects. Avita’s patented and proprietary
collection and application technology provides innovative treatment solutions
derived from a patient’s own skin. The Company’s lead product, ReCell®, is used
in the treatment of a wide variety of burns, plastic, reconstructive and
cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered
in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an
investigational device limited by federal law to investigational use. A pivotal
U.S. trial is underway, with patient enrollment completion anticipated by the
end of 2015. To learn more, visit www.avitamedical.com.

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: +44 (0) 1763 269 772

akelliher@avitamedical.com

 

Avita
Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: + 1 (818) 356-9400

trooney@avitamedical.com

 

 

Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone +61(0) 8 9474 7738

gabriel@laurus.net.au

 

USA

The Ruth Group

Lee Roth, Investor Relations

Kirsten Thomas, Public Relations

Phone: +1 (646) 536-7012 / +1 (508) 280-6592

lroth@theruthgroup.com/ kthomas@theruthgroup.com

 

Australia

Monsoon Communications

Rudi Michelson

Investor Relations / PR

Phone: +61 3 9620 3333

rudim@monsoon.com.au

 

 

 

 

This release includes additional documents. Select the link(s) below to view.

Taiwan Update 12 Oct 2015.pdf

Copyright © 2015 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/AVMXY/news?id=116402

Leave a Reply

WP2Social Auto Publish Powered By : XYZScripts.com
Bunk Beds